Anti-Centromere Ab by EIA (Enzyme Immunoassay)

CPT: 86235
Print Share


  • anti-CENP-A
  • anti-CENP-B
  • anticentromere antibodies

Expected Turnaround Time

10 days

Specimen Requirements




2.0 mL

Minimum Volume

1.0 mL


Gel-barrier tube, red-top tube


Draw blood in gel-barrier tube and centrifuge. If red-top tube is used, centrifuge within 45 minutes of draw, remove the serum, place in a plastic transport tube and tightly stopper the tube.

Storage Instructions

Refrigerated or frozen

Stability Requirements



Room temperature

8 hours


14 days


5 years

Freeze/thaw cycles

Stable x6

Test Details


The presence of anti-centromere antibodies (ACA) is predictive of the development of Systemic Sclerosis (SSc) in either apparently health individuals or in patients with Connective Tissue Disease (CTD).1 ACA is found in approximately 30% of patients with SSc and has a distribution range of 11% to 40% worldwide with greater frequency in Caucasians than Asians or African-Americans.2 ACA is recognized as one of the serological markers of limited SSc with features of long lasting Raynaud's disease and subsequent development of progressive thickening of skin at the extremities, neck and face.1 About 10% to 20% of ACA-positive patients develop pulmonary arterial hypertension.3 ACA has been found to be associated with anti-Ro/SSA (both Ro-52 and Ro-60) in approximately 30% of SSc patients.3 Patients with SSc who are also positive for ACA and anti-mitochondrial antibodies have a higher rate of primary biliary cirrhosis.4

This test detects the presence of anti-centromere-A (CENP-A) and anti-centromere-B (CENP-B) antibodies and reports total anti-centromere antibodies in units without differentiating between anti-CENP-A and anti-CENP-B.

For the detection of other forms of anti-centromere antibodies, please note that there is another test number for Anti-Centromere Ab by IFA (indirect fluorescence/immunofluorescence assay) where total antibodies are reported as a titer.


Enzyme Immunoassay


1. Reveille JD, Solomon DH, ACR Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003 Jun 15;49(3):399-412.1279479
2. Koenig M, Dieudé M, Senécal JL. Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev. 2008 Sep;7(8):588-593.18617021
3. Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13(5):R172.22018289
4. Cavazzana I, Ceribelli A, Traborelli M, et al. Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis. J Rheumatol. 2011 Oct;38(10):2180-2185.21921093


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
169500 Anti-Centromere Ab by EIA 169501 Anti-Centromere Ab by EIA Units Pending

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at